Otsuka Pharmaceutical Co. Ltd. has identified new piperidine- and morpholine-carboxylate compounds acting as sortilin (SORT; NT3; Gp95) antagonists. As such, they are described as potentially useful for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s and Parkinson’s disease.

A Juno Therapeutics Inc. patent describes pyrazole-based DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.

Several French institutions, including the University of Rennes, have prepared and tested disubstituted ferrocene complexes acting as viral replication inhibitors reported to be useful for the treatment of viral infections.

Padarn Therapeutics Inc. has described CDK2/cyclin A2 and CDK1/cyclin A2 inhibitors reported to be useful for the treatment of cancer.

Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, schizophrenia, atypical hemolytic uremic syndrome, membranous nephropathy, myasthenia gravis, paroxysmal nocturnal hemoglobinuria, diabetic retinopathy and rheumatoid arthritis, among others.

Hangzhou Polymed Biopharmaceuticals Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety via a linker reported to be useful for the treatment of cancer.

Jing Medicine Technology (Shanghai) Ltd. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression.

Cytokinetics Inc. has disclosed fast type myosin-binding protein C (MYBPC2) inhibitors reported to be useful for the treatment of neuromuscular disorders.

Humanwell Pharmaceutical US Inc. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.

Hanmi Holdings Co. Ltd. has divulged heterocyclic derivatives acting as inhibitors of eukaryotic translation initiation factor 2-α kinase 4 (GCN2), eukaryotic translation initiation factor 2-α kinase 1 (HRI), eukaryotic translation initiation factor 2-α kinase 3 (PERK) and interferon-induced, double-stranded RNA-activated protein kinase (PKR; EIF2AK2) reported to be useful for the treatment of cancer, Alzheimer’s disease and immunological disorders.